Sethuraman Natarajan has filed 35 insider transactions across 1 company since March 2024.
Most recent transaction: a tax payment of 3898 shares of Entrada Therapeutics, Inc. ($TRDA) on March 02, 2026.
Activity breakdown: 0 open-market purchases and 17 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | F | Common Stock | 3898 | $11.66 | 249,801.0000 | 41,462,567 | 1.54% | 0.01% |
| March 1, 2026 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | A | Common Stock | 55800 | $0.00 | 253,699.0000 | 41,462,567 | 28.20% | 0.13% |
| March 1, 2026 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | A | Stock Option (Right to Buy) | 83200 | $0.00 | 83,200.0000 | 41,462,567 | 9999.99% | 0.20% |
| March 3, 2026 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | F | Common Stock | 7577 | $11.76 | 242,224.0000 | 41,462,567 | 3.03% | 0.02% |
| Sept. 2, 2025 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | F | Common Stock | 1760 | $5.43 | 197,899.0000 | 39,003,169 | 0.88% | 0.00% |
| March 1, 2025 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | A | Common Stock | 60800 | $0.00 | 205,797.0000 | 39,003,169 | 41.93% | 0.16% |
| March 3, 2025 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | F | Common Stock | 6138 | $11.68 | 199,659.0000 | 39,003,169 | 2.98% | 0.02% |
| March 1, 2025 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | A | Stock Option (Right to Buy) | 90800 | $0.00 | 90,800.0000 | 39,003,169 | 9999.99% | 0.23% |
| Dec. 2, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | S | Common Stock | 4088 | $20.26 | 156,700.0000 | 40,629,602 | 2.54% | 0.01% |
| Dec. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | S | Common Stock | 11703 | $20.15 | 144,997.0000 | 40,629,602 | 7.47% | 0.03% |
| Nov. 29, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | S | Common Stock | 100 | $20.00 | 160,788.0000 | 40,629,602 | 0.06% | 0.00% |
| Nov. 11, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | S | Common Stock | 1409 | $20.01 | 163,588.0000 | 40,629,602 | 0.85% | 0.00% |
| Nov. 13, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | S | Common Stock | 2700 | $20.04 | 160,888.0000 | 40,629,602 | 1.65% | 0.01% |
| Nov. 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | S | Common Stock | 749 | $18.02 | 182,467.0000 | 40,629,602 | 0.41% | 0.00% |
| Nov. 5, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | S | Common Stock | 5171 | $18.18 | 177,296.0000 | 40,629,602 | 2.83% | 0.01% |
| Nov. 6, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | S | Common Stock | 9554 | $18.71 | 167,742.0000 | 40,629,602 | 5.39% | 0.02% |
| Nov. 6, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | S | Common Stock | 2745 | $19.32 | 164,997.0000 | 40,629,602 | 1.64% | 0.01% |
| Oct. 16, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | President, Research & Develop. | S | Common Stock | 600 | $18.00 | 183,216.0000 | 40,629,602 | 0.33% | 0.00% |
| Sept. 6, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | S | Common Stock | 600 | $15.24 | 186,458.0000 | 33,050,319 | 0.32% | 0.00% |
| Sept. 9, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | S | Common Stock | 2642 | $15.09 | 183,816.0000 | 33,050,319 | 1.42% | 0.01% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | F | Common Stock | 14 | $17.70 | 188,180.0000 | 33,050,319 | 0.01% | 0.00% |
| Sept. 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | F | Common Stock | 955 | $15.42 | 187,225.0000 | 33,050,319 | 0.51% | 0.00% |
| Sept. 5, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | F | Common Stock | 167 | $15.13 | 187,058.0000 | 33,050,319 | 0.09% | 0.00% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | F | Common Stock | 151 | $16.93 | 188,194.0000 | 33,050,319 | 0.08% | 0.00% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | F | Common Stock | 469 | $15.76 | 188,345.0000 | 33,050,319 | 0.25% | 0.00% |
| July 15, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | S | Common Stock | 638 | $18.00 | 188,814.0000 | 33,050,319 | 0.34% | 0.00% |
| July 12, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | S | Common Stock | 600 | $18.00 | 189,452.0000 | 33,050,319 | 0.32% | 0.00% |
| May 20, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | S | Common Stock | 9675 | $15.19 | 190,052.0000 | 33,050,319 | 4.84% | 0.03% |
| May 16, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | S | Common Stock | 1000 | $15.00 | 208,032.0000 | 33,050,319 | 0.48% | 0.00% |
| May 17, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | S | Common Stock | 8305 | $15.14 | 199,727.0000 | 33,050,319 | 3.99% | 0.03% |
| March 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | F | Common Stock | 414 | $13.37 | 210,537.0000 | 33,050,319 | 0.20% | 0.00% |
| March 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | F | Common Stock | 347 | $12.42 | 210,951.0000 | 33,050,319 | 0.16% | 0.00% |
| March 1, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | A | Common Stock | 44100 | $0.00 | 211,298.0000 | 33,050,319 | 26.38% | 0.13% |
| March 5, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | F | Common Stock | 1505 | $12.28 | 209,032.0000 | 33,050,319 | 0.71% | 0.00% |
| March 1, 2024 | Entrada Therapeutics, Inc. | $TRDA | Sethuraman Natarajan | Chief Scientific Officer | A | Stock Option (Right to Buy) | 66800 | $0.00 | 66,800.0000 | 33,050,319 | 9999.99% | 0.20% |